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ABSTRACT 
 
INTRODUCTION 
Intracardiac thrombi associated with dilated cardiomyopathy in paediatric patients 
can be a source of significant morbidity and mortality. This study looked at the 
prevalence, risk factors and outcomes of children complicated by intracardiac 
thrombi, following a diagnosis of dilated cardiomyopathy at a tertiary centre. 
METHODS 
A retrospective review of all children, between the ages of 1 and 14 years, diagnosed 
with dilated cardiomyopathy from August 1983 to July 2011 were assessed using the 
paediatric cardiology database at Chris Hani Baragwanath Academic Hospital. The 
study population comprised of 303 children. 
RESULTS 
The prevalence of intracardiac thrombi in the children with dilated cardiomyopathy 
was 13.2% (40 children).  The majority were located in the left ventricle (80%). The 
children who developed intracardiac thrombi had a lower fractional shortening 
compared to the group without intracardiac thrombi (p≤0.05). 20 of these children 
(6.6%) had evidence of embolization (15/20 to the central nervous system). 52 of the 
303 children were HIV positive (17.2%). There was no statistically significant 
association between HIV status and the development of intracardiac thrombi (p = 
0.19).  The overall mortality was 8.9%.  12 of the 27 deaths occurred in the 
intracardiac thrombi group showing that the children with intracardiac thrombi had a 
poorer outcome (p≤0.05).  
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CONCLUSION 
Intracardiac thrombi is a common occurrence in paediatric patients with dilated 
cardiomyopathy. There is a significant relationship between the development of 
intracardiac thrombi and a poor fractional shortening. Patients with 
echocardiographic evidence of intracardiac thrombi have a worse outcome.  
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DEFINITIONS 
 
 Dilated cardiomyopathy - characterized by dilatation of the left ventricle or 
both ventricles with impaired contraction2 
 Intracardiac thrombi - echocardiographic finding of an intra-cavitatory mass  
suggestive of a thrombus 
 Systemic embolization - defined as the involvement of the central nervous 
system as evidenced by neurological impairment (stroke) or signs of 
peripheral ischaemia eg. pulselessness, gangrene of a limb  
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LIST OF ABBREVIATIONS 
 
 CHBAH - Chris Hani Baragwanath Academic Hospital 
 CXR – Chest x-ray 
 DCMO - Dilated cardiomyopathy 
 ECG – Electrocardiogram 
 HIV - Human Immunodeficiency Virus  
 IAS - Interatrial septum 
 IQR – Inter-quartile range 
 IVC - Inferior vena cava 
 IVS - Interventricular septum 
 LA – Left atrium 
 LV – Left ventricle 
 LVH – Left ventricular hypertrophy 
 MNTH(S) - Month(s) 
 RA – Right atrium 
 RAH – Right atrial hypertrophy 
 RV – Right ventricle 
 SVC – Superior vena cava 
 YR(S) - Year(s)
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1 CHAPTER ONE - INTRODUCTION  
The occurrence of an intracardiac thrombus in the setting of a dilated 
cardiomyopathy is a serious complication. The potential to embolize can be a 
significant source of morbidity and mortality. The objectives of this study were to 
evaluate the available data and assess the prevalence, associated risk factors and 
outcomes in children with dilated cardiomyopathy complicated by intracardiac 
thrombi. 
1.1  Background and classification 
Cardiomyopathy refers to a group of disorders affecting the myocardium and leading 
to cardiac dysfunction.  
The European Society of Cardiology Working Group on Myocardial and Pericardial 
Diseases1 has recently re-classified Cardiomyopathies into five categories, namely: 
1. Dilated cardiomyopathy 
2. Hypertrophic cardiomyopathy 
3. Restrictive cardiomyopathy 
4. Arrhythmogenic right ventricular cardiomyopathy 
5. Unclassified. 
Dilated cardiomyopathy (DCMO) is the most common form of cardiomyopathy 
(90%)3,6,7  and is characterized by cardiac dilatation and systolic dysfunction (decrease 
in myocardial contractility).4,8,14,26 
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                      Figure 2  Dilated cardiomyopathy 
 Enlargement of cardiac chambers 
 Globular-shaped heart 
 ↓ ventricular wall thickness 
 ↓ contractility  
Figures drawn by author         
  
   
  
 
1.2  Epidemiology 
The incidence of DCMO in children is 0.34-0.73/100000.3,4,5,6,7,8. The advent and 
availability of echocardiography has made the diagnosis of intracardiac thrombi in 
children possible. Previous studies, although few and lacking data from Africa, have 
reported a frequency of intracardiac thrombi of 4-16%14,,15,17,20 in children with 
DCMO and an even higher incidence of 43-57%14,20,21 in paediatric autopsy reports, 
with a male predominance.16,23  Embolism associated with intracardiac thrombi has a 
reported frequency of 2.5-27%,16,18,22 with larger emboli embolizing more 
frequently,16,25 and with the central nervous system more commonly involved.15,18 
 
 
 
 
  
 
 
Figure 1  Normal 
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1.3  Etiology 
The causes of cardiomyopathy may be primary/idiopathic or secondary in etiology. 
The majority of cases (66%) of DCMO, are classified as idiopathic.3,4,8 Other 
etiological categories include:  
 Infectious diseases (e.g. viral-Coxsackie virus, bacterial-Streptococcal)  
 Deposition disorders (e.g. hemochromatosis)  
 Drugs/toxins (e.g. chemotherapeutic agents, antiretroviral agents, lead)  
 Electrolyte abnormalities (e.g. hypocalcemia)  
 Endocrine disorders (e.g. pheochromocytoma, diabetes mellitus)  
 Neuromuscular disorders (e.g. Duchenne muscular dystrophy).26 
1.4  Pathophysiology and classification of intracardiac thrombi 
Impaired left ventricular systolic function, stasis of blood flow, dysrhythmias, a 
hypercoagulable state and abnormal endocardial surfaces, are all factors that have been 
implicated in the pathogenesis of thrombosis.14,15,17,20,21,22 In DCMO the large end-
systolic ventricular volumes causes stasis of blood and this creates a favourable 
environment for the development of intracardiac thrombi.24  Thrombi can be found in 
one or more chambers, but the left ventricle (LV) is the chamber most commonly 
involved.14,16,18,21,22,24   This is followed by the right ventricle, right atrial appendage 
and left atrial appendage, the last three often occurring in association with LV 
thrombus.24 
Intracardiac thrombi can be classified according to location (Table 1).24 
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Table 1  Intracardiac thrombi: classification by location 
 Atrial cavities 
o Left atrium 
 Appendage only 
 Body only 
 “Ball” “massive” 
 Combination  
o Right atrium 
 Appendage only 
 Body only 
 Combination 
 “Migrating” 
o Left and right atria 
 Ventricular cavities 
o Left ventricle 
 With aneurysm 
 Without aneurysm 
o Right ventricle 
 With aneurysm 
 Without aneurysm 
 “Migrating” 
o Left and right ventricles 
 Atrial and ventricular cavities 
 
5 | P a g e  
 
Previously reported studies have found that intracardiac thrombi tend to develop 
during rapid deterioration of ventricular function.14 Falk and Günthard both reported 
a significantly lower fractional shortening (echocardiographic measure of ventricular 
systolic function) in the group with thrombo-embolism, and suggested that a fractional 
shortening of <15% (normal is ≥28%) appeared to be a high risk factor in the paediatric 
population.15,18 
1.5  Diagnosis 
Patients with DCMO present with cardiomegaly and may have features of cardiac 
failure (fatigue, dyspnea, orthopnea, tachycardia, pulmonary oedema, hepatomegaly, 
gallop rhythm) and a systolic murmur (secondary to mitral/tricuspid regurgitation) 
may be audible. The chest X-ray (CXR) shows evidence of cardiomegaly and possibly 
pulmonary congestion. Findings on the electrocardiogram (ECG) may include 
tachycardia, left ventricular/left atrial (LA) hypertrophy or atrial/ventricular 
arrhythmia. Echocardiography will demonstrate chamber enlargement with poor 
contractility (Fig. 2), a reduced shortening fraction and may show evidence of an 
intracardiac thrombus.26  
Although the gold standard for the diagnosis of intracardiac thrombi is direct 
visualization of the characteristic mass at operation or autopsy, two-dimensional trans-
thoracic echocardiography has been shown to be both sensitive (92%) and specific 
(88%),11,12,15,17 and has an advantage of being a non-invasive tool. Despite having been 
shown to be superior, trans-esophageal echocardiography is limited by its need for 
general anesthesia in children and the difficultly of examining the cardiac apex, which 
is a common site for thrombi.13,15,17,20 
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False negative echocardiographic detection can result in those thrombi that are recent 
and less echogenic, whereas false positive echocardiographic detection can be found 
in those cases where the contours of cardiac chambers are irregular.25 
1.6 Complications and prognosis 
The complications of dilated cardiomyopathy include:  
 Cardiac failure 
 Valvular regurgitation 
 Pericardial/pleural effusions 
 Arrhythmias 
 Infective endocarditis 
 Failure to thrive 
 Thrombo-embolic phenomenon 
 Shock  
 Death.26 
DCMO has a very poor prognosis and progressive deterioration is evident in the 
majority of patients. Studies have reported a 5 year survival rate of 60-75%.4,5,10 
Accompanied with its potential to embolize and subsequent vascular occlusion, 
intracardiac thrombosis, if present, is a potential source of significant morbidity and 
mortality.14,15,16 Manifestations of embolism include, neurological impairment 
(hemiplegia), myocardial ischaemia, pulmonary embolus, renal dysfunction, and limb 
involvement (necrosis).  
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Certain echocardiographic-histologic observations regarding risk of embolization 
have been made. Thrombi which are most likely to embolize are recent, mobile, less 
bright, protruding and/or pedunculated. Large thrombi which tend to have liquefied 
central cores also have a tendency to embolise.16,19,25 
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2 CHAPTER TWO - METHODOLOGY  
2.1  Aims  
 To determine the prevalence, risk factors and outcomes of children with dilated 
cardiomyopathy complicated by intracardiac thrombi.  
2.2  Objectives 
 To calculate the prevalence of intracardiac thrombi associated with DCMO in 
children at CHBAH  
 To find risk factors associated with the development of intracardiac thrombi in 
paediatric patients with DCMO at CHBAH  
 To look at the outcomes of children with intracardiac thrombi associated with 
DCMO, as compared to those without, at CHBAH  
2.3  Study design 
A descriptive retrospective record review. 
2.4 Study site 
Data was extracted from the computerized paediatric cardiology database at Chris 
Hani Baragwanath Academic Hospital.  
2.5  Study period 
Data from August 1983 to July 2011 was assessed. 
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2.6 Study population  
 All children aged between 1 and 14 years, diagnosed with DCMO at Chris 
Hani Baragwanath Academic Hospital were entered onto the paediatric 
cardiology database and analysed. This group was then sub divided into 2 
groups:  
A. Children with intracardiac thrombi       
B. Children without intracardiac thrombi                                                                   
 Children < 1 year old were excluded as there were no cases of intracardiac 
thrombi in this age group on review of the data. Children > 14 years were 
excluded as this is the cut-off age for admission to the paediatric wards. 
2.7  Sampling 
2.7.1 Inclusion criteria 
  The diagnostic criteria for dilated cardiomyopathy must have been met 
  Confirmed intracardiac thrombi  by two-dimensional echocardiography 
2.7.2 Exclusion criteria 
 Children < 1 year old and >14 years old  
 Insufficient patient data on the database 
 
2.8 Data instruments 
Data was extracted from the paediatric cardiology database. The data was then 
entered onto a data collection sheet (Appendix A). 
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The data collection sheet included: 
 Demographic characteristics 
- Date of birth and age at first presentation 
- Gender  
 Echocardiogram 
- Date  
-  Findings relating to ventricular function and the presence of an 
intracardiac thrombus  
 Follow-up details 
- Complications related to the thrombus 
- Outcome 
 Associated medical conditions  
2.9 Data collection 
Data was extracted from the paediatric cardiology database and entered onto a data 
collection sheet. 
2.10  Data management 
Data was coded and captured using Microsoft Excel 2007. Some variables needed to 
be defined before they could be analysed.  
 The presence of an intracardiac thrombus was categorized into two groups, 
“yes” if there was echocardiographic evidence of a thrombus or “no” if there 
was no thrombus observed during echocardiography. 
 Embolization was categorized into two groups, “yes” if there was systemic 
signs of embolization and “no” if systemic signs were absent. 
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 Mortality at discharge was categorized into two groups, “survivor” if patient 
survived to hospital discharge and “non-survivor” if patient demised during 
that hospital stay. 
 Anticoagulation was categorized into two groups, “yes” if the children were 
on any anticoagulation treatment and “no” if no record of treatment was 
made. 
 HIV status was categorized into two groups, “positive” if the child was 
confirmed positive and “unknown” if no record of status was made.  
 
2.11 Data analysis 
Data was imported into STATA version 12 for analysis.  
For descriptive purposes, medians (together with interquartile range [IQR]) have 
been reported for all variables related to age and fractional shortening. 
This study used chi square and fisher’s exact tests for all categorical variables. All 
statistical tests were two sided and a P value of ≤ 0.05 was considered statistically 
significant. 
For the purpose of measuring possible risk factors, association statistical tests were 
conducted. The mi command was used to drop the missing values in the two 
variables with missing data (gender and fractional shortening), before testing the 
variable.  
Summary of tests used (Table 2). 
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Table 2  Summary of statistical tests used 
Independent     
variable 
Dependent variable Statistical test 
Age  
(discrete variable) 
Intracardiac thrombus 
(binary variable) 
Logistic regression 
 
HIV status  
(binary variable) 
Intracardiac thrombus 
(binary variable) 
Chi-square 
 
Gender  
(categorical variable) 
Intracardiac thrombus 
(binary variable) 
Welch t-test 
 
Fractional shortening 
(continuous variable) 
Intracardiac thrombus 
(binary variable) 
 Logistic regression 
 
Mortality 
(binary variable) 
Intracardiac thrombus 
(binary variable) 
Fisher exact 
 
 
2.12 Finance 
Due to the retrospective nature of this study, no funding was required. 
2.13  Ethical considerations 
Ethics approval for the purpose of retrospective analyses for publication, was granted 
to the Paediatric Cardiology Department at Chris Hani Baragwanath Academic 
Hospital (Ethics clearance number: Appendix C).  
Ethics clearance was obtained from The Ethics Committee for Research on Human 
Subjects (Medical) at the University of the Witwatersrand (Ethics clearance number: 
Appendix B).  
Permission for the study was also obtained from the Medical Advisory Committee at 
Chris Hani Baragwanath Hospital (Appendix D). 
Confidentiality of patient’s records were maintained. No identifying data fields (name, 
hospital number) were included in the data collection sheet.  
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3 CHAPTER THREE - RESULTS 
3.1 Descriptive analysis 
3.1.1 Study sample 
In order for the study to be adequately powered, a sample size of 298 was required. 
However, upon considering the missing data in some of the patient’s records, the 
sample size was inflated by 5%, increasing the sample size required to 305. 327 
children with DCMO were identified in the paediatric cardiology database. Of these 
24 patients were excluded thus reaching a final sample size of 303 (Children with 
DCMO and intracardiac thrombi [N=40], children with DCMO and no intracardiac 
thrombi [N=263]). (Table 3) 
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Table 3  Demographic data 
 
There are two variables with missing values, gender with 9 missing values, and 
fractional shortening with 74 missing values. 
   Child with 
DCMO and no 
intracardiac 
thrombus 
Children with 
DCMO and 
intracardiac 
thrombus  
All children 
with DCMO 
Age 1-5yrs 132 17 149 
  5yrs 1mnth-10yrs 84 14 98 
  10yrs 1mnth- to 14yrs 47 9 56 
  TOTAL 263 40 303 
          
Gender Male 137 25 162 
  Female 117 15 132 
  TOTAL 254 40 294 
          
HIV Unknown 215 36 251 
  Positive 48 4 52 
  TOTAL 263 40 303 
          
Mortality Survivors 248 28 276 
  Non-survivors 15 12 27 
  TOTAL   263 40 303 
          
Embolization Yes 11 9 20 
  No 252 31 283 
  TOTAL   263 40 303 
          
Fractional 
shortening 
Yes 
194 35 229 
  No 69 5 74 
  TOTAL    263 40 303 
          
Anticoagulation Yes 5 24 29 
  No 258 16 274 
  TOTAL 263 40 303 
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3.1.2 Demographic data 
3.1.2.1 Age 
The age ranged from 1 year to 13.9 years, with the median age at time of 
presentation in the DCMO group of 5.4 years (IQR 2.8, 9) and 6.7 years (IQR 3.3, 
9.5) in the intracardiac thrombi group.  
 
Figure 3  Age distribution in DCMO group 
 
 
Figure 4  Age distribution in intracardiac thrombus group 
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3.1.2.2  Gender 
Males represented 53.4% (162) and females 43.6% (132) of the sample with 3% (9) 
missing data for gender. In the intracardiac thrombus group there were 25 males and 
15 females (no missing data), with a male:female ratio of 1.67:1. 
 
Figure 5  Gender distribution 
 
3.2 Prevalence of intracardiac thrombi in children with DCMO 
Of the 303 children with DCMO, 40 children had echocardiographic evidence of an 
intracardiac thrombus which translated to a prevalence of 13.2% (Patient 
characteristics – Appendix E). The majority were located in the left ventricle (80%).  
Males Females Unknown
53.4%43.6%
3%
17 | P a g e  
 
3.3 Risk factors associated with the development of intracardiac 
thrombi in children with dilated cardiomyopathy 
3.3.1 Age 
17 cases of intracardiac thrombi occurred in the 1-5 year age group. There was 
however, no statistically significant relationship between age and the development of 
intracardiac thrombi (p=0.39). 
3.3.2 Gender 
Being male or female did not increase the risk of developing intracardiac thrombi 
(p=0.31). 
3.3.3 Fractional shortening 
The median fractional shortening in the group with and without an intracardiac 
thrombus was 11% (IQR 7%, 19%) and 16.5% (IQR 12%, 22.8%) respectively (Table 
4). There was a statistically significant difference in fractional shortening between the 
group that developed intracardiac thrombi and the group that did not. The development 
of intracardiac thrombi was significantly associated with a poor fractional shortening 
(p≤0.05). 
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Table 4  Fractional shortening (%) on echocardiography 
3.3.4 Associated conditions 
52 children (17.2%) were HIV positive. There was no significant relationship between 
HIV positive patients and the development of an intracardiac thrombus (p=0.19). 
3.3.5 Anticoagulation 
24 children were reported as being on anticoagulation in the intracardiac thrombi 
group. Only 5 out of the 263 children without intracardiac thrombi were reported as 
being on anticoagulation.  
 
3.4 Outcome of children with dilated cardiomyopathy complicated 
by intracardiac thrombi 
3.4.1 Embolization 
20 children (6.6% of the study population) demonstrated systemic signs of 
embolization. 11 of these children did not demonstrate any intracardiac thrombi at 
the time of the echocardiograph. 15 of the children had emboli to the central nervous 
system (75%). 
 CHILDREN WITH 
INTRACARDIAC THROMBI 
 CHILDREN WITHOUT 
INTRACARDIAC THROMBI 
N 35 194 
MEDIAN (IQR) 11% (7%, 19%) 16.5% (12%, 22.8%) 
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3.4.2 Mortality 
There was a total of 27 deaths in the study population during the first admission. The 
overall mortality during the first admission was 8.9%.  12 of the deaths occurred in 
the intracardiac thrombi group. Children with intracardiac thrombi had a poorer 
outcome as compared to children without the intracardiac thrombi (p≤0.05) (Table 
5). Only 3 deaths were associated with embolization. 
 
Table 5  Outcome data 
 CHILDREN WITH 
INTRACARDIAC THROMBI 
 CHILDREN WITHOUT 
INTRACARDIAC THROMBI 
Embolization 9 (22.5%) 11 (4.2%) 
Survivor 28 (70%) 248 (94.3%) 
Non-survivor 12 (30%) 15 (5.7%) 
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4 CHAPTER FOUR - DISCUSSION 
One of the many complications of DCMO is the development of intracardiac 
thrombi.26 The potential for the intracardiac thrombi to embolize is a significant 
source of morbidity and mortality.14,15,16 Despite this, there is limited information on 
the prevalence, risk factors and outcomes associated with DCMO complicated by 
intracardiac thrombi. Studies to date have been small in terms of sample size and 
have provided no concrete evidence to enable targeted preventative management 
guidelines. 
Our study sample included 303 DCMO patients, 40 of whom were complicated by 
the development of intracardiac thrombi, which to our knowledge, is one of the 
largest studies to date. Sample sizes of studies reviewed ranged from 25 in the 
Boston study,18 to 130 in the Swiss study,15 with limited data from Africa. 
4.1 Demographic data 
4.1.1 Age 
The median age at diagnosis of DCMO was 5.4 years (IQR 2.8, 9). The DCMO 
children in this study presented at a much later age compared to the reviewed 
studies. In the earlier studies reviewed, children usually presented at around 2 years 
of age however these studies also included children under 1 year of age in their 
cohort of patients.3,4,6,8 The delayed presentation at the time of diagnosis, as 
compared to the other studies, may be attributed to the poor socio-economic status of 
the families in this study population, the long distances occasionally travelled to the 
tertiary centre, the delay in accessing  healthcare services and the possible delay in 
referring the children to a tertiary centre.  
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The median age at diagnosis of intracardiac thrombi was 6.7 years (IQR 3.3, 9.5). 
This value is not vastly different from a value of 8.8 years reported by John et al in 
the Texan study.16 
4.1.2 Gender 
Overall, females and males were equally represented in the DCMO group with a 
ratio of 1:1.23. The 9 missing data did not significantly affect the ratio. The other 
studies that were reviewed demonstrated a male predominance.4,6,17 
In the intracardiac thrombi group (no missing data for gender), the female to male 
ratio was 1:1.67. This value is similar to the Texan study which also revealed a male 
predominance with a ratio of 1:2.4.16   
4.2 Prevalence of intracardiac thrombi in children with DCMO 
The prevalence of intracardiac thrombi in patients with DCMO at CHBAH was 
13.2%. This correlates well with the current literature which cites a value of between 
4% and 16%.14,15,17,19,20 There is an even higher incidence in autopsy reports,14,15,17,20 
however, this could not be confirmed as details regarding autopsy were not available. 
Most of intracardiac thrombi were located in the LV, this is consistent with the 
Korean, Texan and Japanese study.14,16,21 
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4.3 Risk factors associated with the development of intracardiac 
thrombi in children with dilated cardiomyopathy 
4.3.1 Gender 
Although our study showed a male predominance as in the Texan study16, there was 
no statistically significant relationship between gender and the development of 
intracardiac thrombi (p=0.31).   
4.3.2 Fractional shortening and anticoagulation 
The median fractional shortening in the intracardiac thrombi group was 11% (IQR 
7%, 19%), and 16.5% (IQR 12%, 22.8%) in the group without intracardiac thrombi. 
Children presenting with intracardiac thrombi were found to have a significantly 
poorer fractional shortening compared to the group of children without intracardiac 
thrombi. 
The significant relationship between a low FS and the development of intracardiac 
thrombi is a finding consistent with the Korean, Swiss and Boston studies.14,15,18 One 
of the treatment modalities of DCMO includes anticoagulants. This is to reduce the 
risk of emboli in high risk patients.15,26 From the information gathered children with 
a FS of <15% are at high risk for the development of intracardiac thrombi, and 
despite there being a lack of evidence, a recommendation for prophylactic 
anticoagulation can be made in those children with poor cardiac function.  
Children with an intracardiac thrombus were more likely to be on anticoagulation as 
treatment was initiated as soon as the intracardiac thrombi was diagnosed. 
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4.4 Outcomes 
4.4.1 Embolization  
6.6% of the study population showed systemic signs of embolization. This is not 
vastly different form the Boston study of 8.4%.18 Other studies have reported 
between 2.5-27%19 with the Texan and Japanese study showing that 13% and 17.5% 
of patients showed signs of embolization respectively.16,21 Embolization to the 
central nervous system was predominant (75%), and this is in keeping with the Swiss 
and Boston study.15,18  
Some children who demonstrated signs of embolization did not show an intracardiac 
thrombus on echocardiography, and this could be due to the thrombus having 
embolized. If we assumed that the group that showed embolization without any 
visible intracardiac thrombi, had developed intracardiac thrombi at some point 
following their disease then this assumption would increase the prevalence of 
intracardiac thrombi in patients with DCMO to 16.8%.  This still correlates well with 
the current literature.14,15,17,19,20  
4.4.2 Mortality 
Despite presenting at an older age, 91.1% of the study population survived during the 
first admission (due to missing data, a follow-up period could not be established). The 
Egyptian (follow-up period 36.2 ±22.1 months), Saudi Arabian (followed-up period 
34.7 ±23.2 months) and London study (follow-up period 19 months) showed that the 
older the age of presentation, the worse the prognosis.3,8,10 Studies have reported a 5 
year survival rate of 60-75% in patients with DCMO.4,5,10 
 
24 | P a g e  
 
The mortality in the ICT group was 30%, which is slightly less than in the Texas and 
Toronto studies, which quoted a mortality of 39% and 37.5% respectively.16,17  
A significantly worse outcome was demonstrated in the intracardiac thrombi group. 
Other concomitant illnesses were not taken into consideration and this could have 
influenced the result. 
4.5 Limitations 
Limitations of the study are as follows: 
1. It is representative of a single tertiary institution of a low socio-economic 
status.  
2. The missing information from the database required adjustments to be made 
by statistical calculations.  
3. Retrospective data analysis whereby we could only account for mortality rate 
at the time of first admission. A long term follow-up of these children with a 
more detailed analysis including the cause of mortality would be useful. 
4. The use of two-dimensional transthoracic echocardiography to diagnose 
intracardiac thrombi has been found to be very sensitive and specific,11,12,15,17 
however, it is operator dependant and there is the possibility of missed 
thrombi. Trans-oesophageal echocardiography, found to be more superior to 
transthoracic echocardiography, 13,15,17,20  was not used. 
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5 CHAPTER FIVE - CONCLUSION  
This study is one of the largest studies to date investigating intracardiac thrombi in 
patients with DCMO. The data presented in this study, despite its limitations, 
demonstrates a prevalence of intracardiac thrombi in patients with DCMO in keeping 
with the current literature. There is a significant relationship with the development of 
intracardiac thrombi and a poor fractional shortening. Patients with 
echocardiographic evidence of intracardiac thrombi have a worse outcome.  
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6 CHAPTER SIX - RECOMMENDATIONS 
The need for regular follow-up and the commencement of prophylactic 
anticoagulation in patients with poor fractional shortening and their impact on 
outcome requires further trials. In particular, future prospective multicenter trials are 
required to assess the benefits of anticoagulation in the prevention of intracardiac 
thrombus in children with DCMO.  
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APPENDIX A – Data collection sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 
number 
 
  
DATA COLLECTION SHEET 
A Descriptive Retrospective Record review of Paediatric patients with Intracardiac thrombi associated 
with dilated cardiomyopathy at CHBAH 
 
Date of birth: 
Gender: 
 
Date of first presentation: 
Age: 
Features of Thrombi: 
Date diagnosed: 
Number   
Location   
Shortening Fraction  
 
Follow-up: 
Date     
Echocardiograph     
Outcome     
 
 
Associated conditions:  
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APPENDIX B – Ethics clearance certificate 
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APPENDIX C - Ethics clearance certificate for paediatric     
                                    cardiology database 
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APPENDIX D – Hospital permission letter 
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APPENDIX E – Characteristics of children with intracardiac  
                             thrombi 
 
N
O. 
AGE (at first 
presentation) 
GENDER SITE FS (at time of thrombus) EMBOLIZATION OUTCOME (with 
discharge) 
HIV STATUS 
1 1 yr 1 mnth Male LV 6% Yes Survivor Unknown 
2 1 yr 1 mnth Male LA 20% No Survivor Positive 
3 1 yr 3 mnths Male LV Unknown No Non-survivor Unknown 
4 1 yr 10 mnths Male LV 12% Yes Survivor Unknown 
5 1 yr 11 mnths Male LV 24% No Survivor Unknown 
6 2 yrs 1 mnth Male LV 16% No Non-survivor Unknown 
7 3 yrs 1 mnth Male LV 6% No Survivor Unknown 
8 3 yrs 1 mnth Male LV, IVS 8% No Survivor Unknown 
9 3 yrs 2 mnths Female LV 23% No Survivor Unknown 
10 3 yrs 2 mnths Female LV 10% No Survivor Unknown 
11 3 yrs 3 mnths Male LV, RV Unknown No Non-survivor Unknown 
12 3 yrs 4 mnths Female LV 11% No Survivor Positive 
13 3 yrs 6 mnths Male LV, IVS 7% Yes Survivor Unknown 
14 3 yrs 6 mnths Male LV 10% No Non-survivor Unknown 
15 4 yrs 4 mnths Male LV 18% No Survivor Unknown 
16 4 yrs 6 mnths Female LV 9% Yes Non-survivor Unknown 
17 4 yrs 7 mnths Male IVC/RA 
junction 
14% No Survivor Unknown 
18 5 yrs 7 mnths Male LV 24% No Non-survivor Positive 
19 6 yrs 1 mnth Male LV 2% No Survivor Unknown 
20 6 yrs 3 mnths Female IAS 14% No Survivor Unknown 
21 6 yrs 9 mnths Female LV 25% No Non-survivor Unknown 
22 7 yrs 2 mnths Male LA 10% Yes Non-survivor Unknown 
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23 7 yrs 5 mnths Male LV, RV Unknown No Non-survivor Unknown 
24 7 yrs 9 mnths Male LV Unknown No Survivor Unknown 
25 7 yrs 10 mnths Male LV, IVS 16% No Survivor Unknown 
26 8 yrs 1 mnth Female LA 5% No Survivor Unknown 
27 8 yrs 2 mnths Female LV, LA 6% Yes Survivor Unknown 
28 8 yrs 4 mnths Female LV 5% No Survivor Unknown 
29 8 yrs 4 mnths Male Unknown 7% No Non-survivor Unknown 
30 8 yrs 10 mnths Female LV 12% Yes Survivor Unknown 
31 9 yrs 6 mnths Female LV 13% No Survivor Unknown 
32 10 yrs 7 mnths Female RV 10% No Survivor Unknown 
33 11 yrs 1 mnth Female LV 7% No Survivor Unknown 
34 11 yrs 4 mnths Male LV 30% No Survivor Unknown 
35 11 yrs 5 mnths Female Unknown 29% Yes Survivor Unknown 
36 11 yrs 10 
mnths 
Male LV 4.5% No Non-survivor Unknown 
37 12 yrs 2 mnths Male LV 10% No Survivor Unknown 
38 12 yrs 6 mnths Male LV, RV Unknown Yes Non-survivor Unknown 
39 12 yrs 6 mnths Female SVC/RA 
junction 
15% No Survivor Positive 
40 13 yrs 9 mnths Male LV 4% No Survivor Unknown 
 
 
